Clinical Trials Logo

Atrophy clinical trials

View clinical trials related to Atrophy.

Filter by:

NCT ID: NCT05386680 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

STRENGTH
Start date: January 12, 2023
Phase: Phase 3
Study type: Interventional

This is an open-label, single arm, multi-center study. Approximately 28 participants aged 2 to <18 years will be enrolled stratified as 2 to 5 years and 6 to < 18 years. The study is comprised of 3 periods, Screening (up to 45 days), Treatment (1 day), and Follow-up (52 weeks).

NCT ID: NCT05379153 Not yet recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Start date: December 2024
Phase: Phase 3
Study type: Interventional

This phase III trial tests whether vaginal fractional CO2 laser therapy works in treating vaginal dryness in breast cancer survivors. Vaginal dryness can be commonly experienced with normal aging, with menopause, or come about from medications used to treat breast cancer such as chemotherapy or endocrine therapies like tamoxifen or aromatase inhibitors. Vaginal fractional CO2 laser therapy may help reduce vaginal dryness.

NCT ID: NCT05378269 Completed - Vulvar Atrophy Clinical Trials

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA

DARE-VVA1
Start date: November 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.

NCT ID: NCT05367973 Completed - Clinical trials for Vulvovaginal Atrophy

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

DARE-HRT1
Start date: April 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized, Open-label 2-arm, parallel group study in approximately 20 healthy postmenopausal women to assess the safety of DARE-HRT1 Intravaginal Rings in two different dose strengths and the PK of progesterone and estradiol from the Intravaginal Rings.

NCT ID: NCT05366465 Recruiting - Clinical trials for Spinal Muscular Atrophy

Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France

QOLSMA
Start date: October 19, 2022
Phase:
Study type: Observational

Spinal muscular atrophy is a hereditary motorneuron disease caused by a mutation of the SMN1 gene, which is at the origin of a progressive limb and axial motor deficiency. It concerns 1200 individuals in France, including 700 adults in 2018. The main objective of this study is to assess the quality of life of SMA patients in France. The secondary objectives are, in one hand, to compare the quality of life of SMA patients to a population of neuromuscular diseases patients. And on the other hand to evaluate the determinants of participation and the impact of participation on quality of life in adult SMA patients.

NCT ID: NCT05354414 Recruiting - Clinical trials for Spinal Muscular Atrophy (SMA)

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy

REALITY
Start date: May 9, 2022
Phase: N/A
Study type: Interventional

The primary objective of the study is to evaluate anxiety level during intrathecal administration (IT) under standard of care (SOC) and virtual reality (VR) conditions using a reliable self-rating scale.

NCT ID: NCT05352620 Completed - Edentulous Jaw Clinical Trials

Smart Box With OT Equator Attachment in Retaining Implant-assisted Overdenture for the Atrophic Maxilla.

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The aim of the present study is to clinically and radiographically evaluate the effect of the use of recently developed Smart Box accompanied with OT Equator attachment in retaining of the inclined implant assisted overdenture for atrophic maxilla and to compare the vertical bone changes around axial implants with OT Equator attachment and inclined implants with smart box attachment radiographically using CBCT

NCT ID: NCT05343572 Recruiting - Clinical trials for Recurrent Implantation Failure

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Start date: November 1, 2023
Phase: Early Phase 1
Study type: Interventional

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

NCT ID: NCT05341453 Recruiting - Clinical trials for Spinal Muscular Atrophy

Hippotherapy in Children With Spinal Muscular Atrophy

HIPOSMA
Start date: April 22, 2022
Phase: N/A
Study type: Interventional

The randomized controlled trial is aimed to discover the physiotherapy and hippotherapy effect and efficacy on children with SMA. The concept is to utilized two types of physiotherapy - the first concept is classic physiotherapy and the second one is hippotherapy. The hippotherapy concept will be in intervals of 15 minutes twice a day, the physiotherapy will be in intervals of 30 minutes once a day. In-patient therapy will be for 6 days. The efficacy will be assessed by biomedical measures - Qualisys Motion Capture Systems 2020.3., by molecular biological markers (lncRNA) in blood and by surface electromyography (EMG). The primary goal of this study is to compare two physiotherapeutic approaches - the recommended form of classical physiotherapy and the method on a neurophysiological basis - hippotherapy. The secondary intention of the research will be the appropriate intensity of therapy so that unwanted muscle fatigue does not occur.

NCT ID: NCT05337553 Active, not recruiting - Clinical trials for Neuromuscular Diseases

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

RESILIENT
Start date: July 6, 2022
Phase: Phase 3
Study type: Interventional

This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen or risdiplam or have a history of onasemnogene abeparvovec-xioi, compared to placebo.